Project/Area Number |
16K11016
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Urology
|
Research Institution | University of the Ryukyus |
Principal Investigator |
Saito Seiichi 琉球大学, 医学(系)研究科(研究院), 教授 (80235043)
|
Co-Investigator(Kenkyū-buntansha) |
須田 哲司 琉球大学, 医学(系)研究科(研究院), 助教 (40423347)
仲西 昌太郎 琉球大学, 医学(系)研究科(研究院), 助教 (40725321)
呉屋 真人 琉球大学, 医学部附属病院, 講師 (50295317)
|
Research Collaborator |
Miyata Yasuyoshi
|
Project Period (FY) |
2016-04-01 – 2019-03-31
|
Project Status |
Completed (Fiscal Year 2018)
|
Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Keywords | prostate cancer / high-grade cancer / glycoprotein / SSEA-4 / 前立腺癌 / 高悪性度腺癌 / 糖鎖 / モノクローナル抗体RM2 / モノクローナル抗体RM1 / 悪性度 / マーカー |
Outline of Final Research Achievements |
We identified molecules related to the malignant potential of prostate cancer in prostate cancer cell lines. Those included enzyme protein (prostate cancer glycoprotein-enzyme: PCGP-enz), glyprotein (GP) related to glycolysis (PCGP-glyco)、GP related to blood pressre (PCGP-bp), GP related to stress response (PCGP-stress), GP related to ubiquitin (PCGP-ub), GP commonly expressed in triple negative breast cancer (PCGP-br), GP commonly expressed in lung cancer (PCGP-lc), GP expressed in endoplasmic reticulum (PCGP-er), etc. Among those PCGP-lc and PCGP-er were significantly associated with higher Gleason score and PCGP-er was also significantly related to T stage using radical prostatectomy specimens. We also found stage-specific embryonic antigen-4 (SSEA-4) was significantly associated with the malignant behavior of prostate cancer using clinical samples.
|
Academic Significance and Societal Importance of the Research Achievements |
現在早期前立腺癌の発見に貢献している血清PSAは悪性度判定ができないため、悪性度を判定できる新しいマーカーが必要とされている。本研究で悪性度の高い前立腺癌細胞内に現れる分子をいくつか同定した。実際の前立腺摘出術標本を用いて悪性度との関連も確認した。今後、これらの分子の中で前立腺癌患者さんの血清中にも検出されるものがあるか否かを確かめる予定である。高悪性度の前立腺癌が血清でわかるようになれば、積極的な治療が必要になり、命取りにならないようなら経過観察の適応が出て来るため、将来の臨床判断に役立てられるかもしれない。
|